First-in-Human Study in Healthy Subjects with the Noncytotoxic Monoclonal Antibody OSE-127, a Strict Antagonist of IL-7Rα
- 15 March 2023
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 210 (6) , 753-763
Abstract
OSE-127 is a humanized mAb targeting the IL-7Rα-chain (CD127), under development for inflammatory and autoimmune disease treatment. It is a strict antagonist of the IL-7R pathway, is not internalized by target cells, and is noncytotoxic. In this work, a first-in-human, phase I, randomized, double-blind, placebo-controlled, single-center study was carried out to determine the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of OSE-127 administration. Sixty-three healthy subjects were randomly assigned to nine groups: six single ascending dose groups with i.v. administration (0.002–10 mg/kg), a single s.c. treatment group (1 mg/kg), and two double i.v. injection groups (6 or 10 mg/kg). Subjects were followed during 100 d after two i.v. infusions at 10 mg/kg. IL-7 consumption was inhibited by OSE-127 administration, as demonstrated by a decreased IL-7 pathway gene signature in peripheral blood cells and by ex vivo T lymphocyte restimulation experiments. OSE-127 was well tolerated, with no evidence of cytokine-release syndrome and no significant alteration of blood lymphocyte counts or subset populations. Altogether, the observed lack of significant lymphopenia or serious adverse events, concomitant with the dose-dependent inhibition of IL-7 consumption by target cells, highlights that OSE-127 may show clinical activity in IL-7R pathway–involved diseases.Keywords
Funding Information
- Bpifrance (Effimab grant I 1302011W)
This publication has 61 references indexed in Scilit:
- Anti–IL-7 receptor-α reverses established type 1 diabetes in nonobese diabetic mice by modulating effector T-cell functionProceedings of the National Academy of Sciences, 2012
- IL-7 receptor blockade reverses autoimmune diabetes by promoting inhibition of effector/memory T cellsProceedings of the National Academy of Sciences, 2012
- IL-7 signaling and CD127 receptor regulation in the control of T cell homeostasisSeminars in Immunology, 2012
- Structural reorganization of the interleukin-7 signaling complexProceedings of the National Academy of Sciences, 2012
- Interleukin‐7 promotes the survival of human CD4+ effector/memory T cells by up‐regulating Bcl‐2 proteins and activating the JAK/STAT signalling pathwayImmunology, 2010
- Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1Nature, 2009
- New insights into the regulation of T cells by γc family cytokinesNature Reviews Immunology, 2009
- Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetesNature Genetics, 2007
- CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cellsJournal of Experimental Medicine, 2006
- Interleukin 7 Regulates the Survival and Generation of Memory CD4 CellsJournal of Experimental Medicine, 2003